Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature

[1] Gan HK(2015)Management of glioblastoma in Victoria, Australia (2006–2008) J Clin neuroscience: official J Neurosurgical Soc Australasia 22 1462-1466

[2] Rosenthal MA(1991)A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party Br J Cancer 64 769-774

[3] Cher L(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[4] Dally M(2020)Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): preliminary results of NRG Oncology BN001" Int J Radiat Oncol Biol Phys 108 S22-S23

[5] Drummond K(2013)Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 4085-4091

[6] Murphy M(2014)Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma New Eng J Med 20 709-722

[7] Bleehen NM(2014)Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071 – 22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet oncol 15 1100-1108

[8] Stenning SP(2006)An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor Int J Radiat Oncol Biol Phys 64 1570-1580

[9] Stupp R(2012)Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 916-926

[10] Mason WP(2004)Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 1583-1588

[1] Gan HK(2015)Management of glioblastoma in Victoria, Australia (2006–2008) J Clin neuroscience: official J Neurosurgical Soc Australasia 22 1462-1466

[2] Rosenthal MA(1991)A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party Br J Cancer 64 769-774

[3] Cher L(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996

[4] Dally M(2020)Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): preliminary results of NRG Oncology BN001" Int J Radiat Oncol Biol Phys 108 S22-S23

[5] Drummond K(2013)Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 4085-4091

[6] Murphy M(2014)Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma New Eng J Med 20 709-722

[7] Bleehen NM(2014)Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071 – 22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet oncol 15 1100-1108

[8] Stenning SP(2006)An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor Int J Radiat Oncol Biol Phys 64 1570-1580

[9] Stupp R(2012)Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 916-926

[10] Mason WP(2004)Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 1583-1588